Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393281 | 1.00 | TMPRSS2 (0.44) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22142989 | 1.00 | TMPRSS2 (0.44) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18605972 | 1.00 | TMPRSS2 (0.44) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL26878544 | 1.00 | TMPRSS2 (0.44) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL26326095 | 1.00 | TMPRSS2 (0.44) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30418526 | 1.00 | TMPRSS2 (0.44) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30921711 | 0.92 | TMPRSS2 (0.39) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30939869 | 0.92 | TMPRSS2 (0.39) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25909437 | 0.91 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL12393441 | 0.89 | TMPRSS2 (0.42) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-113549120-B | Method for preparing ribonucleoside | 吉利德科学公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-108348526-B | Methods of treating arenaviridae and coronaviridae viral infections | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119661537-A | Nucleoside compound, preparation method thereof, composition thereof and application of nucleoside compound in medicine | 中国科学院上海药物研究所 | 2025-03-21 | — | — | CN | disclosed |
| CN-118994170-A | Process for preparing 1' -cyanonucleosides | 吉利德科学公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118812607-A | Method for preparing ribonucleoside | 吉利德科学公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118786128-A | Compounds and methods for treating viral infections | 吉利德科学公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113620992-B | Methods of treating infection by a virus of the family filoviridae | 吉利德科学公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-115298181-B | Process for preparing 1' -cyanonucleosides | 吉利德科学公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118165034-A | Nucleotide compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| CN-115703796-A | Preparation method of important intermediate of Reidesciclovir | 苏州恩泰新材料科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-115298181-A | Process for preparing 1' -cyanonucleosides | 吉利德科学公司 | 2022-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885PI4KA 4317/4885PI4K2B 4583/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885PI4KA 4317/4885PI4K2B 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.